open access

Vol 29, No 3 (2022)
Original Article
Submitted: 2020-05-12
Accepted: 2020-07-23
Published online: 2020-08-11
Get Citation

Impact of successful restoration of sinus rhythm in patients with atrial fibrillation and acute heart failure: Results from the Korean Acute Heart Failure registry

Youngjin Cho1, Il-Young Oh1, Jin Joo Park1, Byung-Hee Oh2, Eun-Seok Jeon3, Jae-Joong Kim4, Kyung-Kuk Hwang5, Myeong-Chan Cho5, Shung Chull Chae6, Sang Hong Baek7, Seok-Min Kang8, Byung-Su Yoo9, Youngkeun Ahn10, Dong-Ju Choi1
DOI: 10.5603/CJ.a2020.0103
·
Pubmed: 32789837
·
Cardiol J 2022;29(3):472-480.
Affiliations
  1. Department of Internal Medicine, Seoul National University Bundang Hospital, Korea
  2. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
  3. Department of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, Korea
  4. Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea
  5. Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
  6. Department of Internal Medicine, Kyungpook National University College of Medicine, Daegu, Korea
  7. Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea
  8. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
  9. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
  10. Department of Internal Medicine, Heart Research Center of Chonnam National University, Gwangju, Korea

open access

Vol 29, No 3 (2022)
Original articles — Clinical cardiology
Submitted: 2020-05-12
Accepted: 2020-07-23
Published online: 2020-08-11

Abstract

Background: Restoring and maintaining sinus rhythm (SR) in patients with atrial fibrillation (AF) failed to show superior outcomes over rate control strategies in prior randomized trials. However, there is sparse data on their outcomes in patients with acute heart failure (AHF).
Methods: From December 2010 to February 2014, 5,625 patients with AHF from 10 tertiary hospitals were enrolled in the Korean Acute Heart Failure registry, including 1,961 patients whose initial electrocardiogram showed AF. Clinical outcomes of patients who restored SR by pharmacological or electrical cardioversion (SR conversion group, n = 212) were compared to those of patients who showed a persistent AF rhythm (AF persistent group, n = 1,662).
Results: All-cause mortality both in-hospital and during the follow-up (median 2.5 years) were significantly lower in the SR conversion group than in the AF persistent group after adjustment for risk factors (adjusted hazard ratio [HR]; 95% confidence interval [CI] = 0.26 [0.08–0.88], p = 0.031 and 0.59 [0.43–0.82], p = 0.002, for mortality in-hospital and during follow-up, respectively). After 1:3 propensity score matching (SR conversion group = 167, AF persistent group = 501), successful restoration of SR was associated with lower all-cause mortality (HR [95% CI] = 0.68 [0.49–0.93], p = 0.015), heart failure rehospitalization (HR [95% CI] = 0.66 [0.45–0.97], p = 0.032), and composite of death and heart failure rehospitalization (HR [95% CI] = 0.66 [0.51–0.86], p = 0.002).
Conclusions: Patients with AHF and AF had significantly lower mortality in-hospital and during follow-up if rhythm treatment for AF was successful, underscoring the importance of restoring SR in patients with AHF.

Abstract

Background: Restoring and maintaining sinus rhythm (SR) in patients with atrial fibrillation (AF) failed to show superior outcomes over rate control strategies in prior randomized trials. However, there is sparse data on their outcomes in patients with acute heart failure (AHF).
Methods: From December 2010 to February 2014, 5,625 patients with AHF from 10 tertiary hospitals were enrolled in the Korean Acute Heart Failure registry, including 1,961 patients whose initial electrocardiogram showed AF. Clinical outcomes of patients who restored SR by pharmacological or electrical cardioversion (SR conversion group, n = 212) were compared to those of patients who showed a persistent AF rhythm (AF persistent group, n = 1,662).
Results: All-cause mortality both in-hospital and during the follow-up (median 2.5 years) were significantly lower in the SR conversion group than in the AF persistent group after adjustment for risk factors (adjusted hazard ratio [HR]; 95% confidence interval [CI] = 0.26 [0.08–0.88], p = 0.031 and 0.59 [0.43–0.82], p = 0.002, for mortality in-hospital and during follow-up, respectively). After 1:3 propensity score matching (SR conversion group = 167, AF persistent group = 501), successful restoration of SR was associated with lower all-cause mortality (HR [95% CI] = 0.68 [0.49–0.93], p = 0.015), heart failure rehospitalization (HR [95% CI] = 0.66 [0.45–0.97], p = 0.032), and composite of death and heart failure rehospitalization (HR [95% CI] = 0.66 [0.51–0.86], p = 0.002).
Conclusions: Patients with AHF and AF had significantly lower mortality in-hospital and during follow-up if rhythm treatment for AF was successful, underscoring the importance of restoring SR in patients with AHF.

Get Citation

Keywords

atrial fibrillation, acute heart failure, cardioversion

About this article
Title

Impact of successful restoration of sinus rhythm in patients with atrial fibrillation and acute heart failure: Results from the Korean Acute Heart Failure registry

Journal

Cardiology Journal

Issue

Vol 29, No 3 (2022)

Article type

Original Article

Pages

472-480

Published online

2020-08-11

Page views

5080

Article views/downloads

857

DOI

10.5603/CJ.a2020.0103

Pubmed

32789837

Bibliographic record

Cardiol J 2022;29(3):472-480.

Keywords

atrial fibrillation
acute heart failure
cardioversion

Authors

Youngjin Cho
Il-Young Oh
Jin Joo Park
Byung-Hee Oh
Eun-Seok Jeon
Jae-Joong Kim
Kyung-Kuk Hwang
Myeong-Chan Cho
Shung Chull Chae
Sang Hong Baek
Seok-Min Kang
Byung-Su Yoo
Youngkeun Ahn
Dong-Ju Choi

References (25)
  1. Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation. 2017; 135(16): 1547–1563.
  2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019; 74(1): 104–32.
  3. January CT, Wann LS, Alpert JS, et al. Jr., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): e1–76.
  4. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23): 1825–1833.
  5. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358(25): 2667–2677.
  6. Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. Eur J Heart Fail. 2014; 16(6): 700–708.
  7. Lim NK, Lee SE, Lee HY, et al. Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J. 2017; 47(3): 341–353.
  8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23): 1834–1840.
  9. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992; 20(3): 527–532.
  10. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2011; 57(2): 223–42.
  11. Braunwald E. Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities. N Engl J Med. 1997; 337(19): 1360–1369.
  12. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009; 119(18): 2516–2525.
  13. Kajimoto K, Sato N, Takano T, et al. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Relationship of renal insufficiency and clinical features or comorbidities with clinical outcome in patients hospitalised for acute heart failure syndromes. Eur Heart J Acute Cardiovasc Care. 2016; 6(8): 697–708.
  14. Santhanakrishnan R, Wang Na, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016; 133(5): 484–492.
  15. Dries D, Exner D, Gersh B, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998; 32(3): 695–703.
  16. Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009; 11(7): 676–683.
  17. Chamberlain AM, Redfield MM, Alonso A, et al. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail. 2011; 4(6): 740–746.
  18. Zareba W, Steinberg J, McNitt S, et al. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm. 2006; 3(6): 631–637.
  19. Torp-Pedersen C, Møller M, Bloch-Thomsen P, et al. Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction. N Engl J Med. 1999; 341(12): 857–865.
  20. Anselmino M, Matta M, Castagno D, et al. Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives. Europace. 2016; 18(5): 638–647.
  21. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7(1): 31–38.
  22. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013; 61(18): 1894–1903.
  23. Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016; 133(17): 1637–1644.
  24. Ullah W, Ling LH, Prabhu S, et al. Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death. Europace. 2016; 18(5): 679–686.
  25. Marrouche N, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378(5): 417–427.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl